GM-CSF (human) (rec.) (His)
|Synonyms||CSF; CSF2; GMCSF; GM-CSF; Molgramostin; Sargramostim; Colony-stimulating Factor; Granulocyte-macrophage Colony-stimulating Factor|
|Sequence||Human GM-CSF (aa 18-144) is fused at the C-terminus to a His-tag.|
|Biological Activity||Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 0.1-0.6 ng/mL.|
|Endotoxin Content||<0.1EU/µg protein (LAL test; Lonza).|
Reconstitute 10µg vial with 100 µl sterile water to a concentration of 0.1mg/ml.
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in 50mM Tris-HCl, 200mM NaCl, pH8.0.|
|Other Product Data||NCBI reference AAI14000.1: GM-CSF (human)|
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Human GM-CSF is a 24 kDa glycoprotein produced by a variety of cell types, including T and B lymphocytes, macrophages, keratinocytes, eosinophils, neutrophils, and endothelial cells in response to cytokine or inflammatory stimuli. GM-CSF was initially identified on the basis of its capacity to stimulate the clonal proliferation of myeloid precursors in vitro. GM-CSF promotes a Th1 biased immune response, allergic inflammation, and the development of autoimmunity. GM-CSF are particularly effective as antitumor vaccines. GM-CSF regulates multiple biological activities through activation of the GM-CSF receptor (GMCSFR), a member of the type I cytokine receptor group comprising α and β subunits.